MAPT and Alzheimer disease: The current revised diagnostic guidelines for AD suggest that AD can be defined in living persons as a biological construct identifiable by changes in biomarkers that are indicative of the disease neuropathology independent of the manifestation of clinical symptoms; for example, the increased tau protein levels in cerebral spinal fluids (Jack et al., 2018).